534 related articles for article (PubMed ID: 27885457)
1. [PSMA-targeted radioligand therapy in prostate cancer].
Heck MM; Retz M; Tauber R; Knorr K; Kratochwil C; Eiber M
Urologe A; 2017 Jan; 56(1):32-39. PubMed ID: 27885457
[TBL] [Abstract][Full Text] [Related]
2. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
3. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [
Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC
Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643
[TBL] [Abstract][Full Text] [Related]
4. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
[TBL] [Abstract][Full Text] [Related]
5. Third-line treatment and
von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
[TBL] [Abstract][Full Text] [Related]
6. [PSMA radioligand therapy in patients with advanced prostate cancer].
Bögemann M; Herrmann K; Radtke JP; Rahbar K
Urologe A; 2020 Jun; 59(6):680-686. PubMed ID: 32333064
[TBL] [Abstract][Full Text] [Related]
7. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U
J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056
[TBL] [Abstract][Full Text] [Related]
8. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
Afshar-Oromieh A; Babich JW; Kratochwil C; Giesel FL; Eisenhut M; Kopka K; Haberkorn U
J Nucl Med; 2016 Oct; 57(Suppl 3):79S-89S. PubMed ID: 27694178
[TBL] [Abstract][Full Text] [Related]
9. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW
Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965
[TBL] [Abstract][Full Text] [Related]
10.
Fendler WP; Rahbar K; Herrmann K; Kratochwil C; Eiber M
J Nucl Med; 2017 Aug; 58(8):1196-1200. PubMed ID: 28663195
[No Abstract] [Full Text] [Related]
11. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
12. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
[No Abstract] [Full Text] [Related]
14. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946
[TBL] [Abstract][Full Text] [Related]
15. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
16. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
18. Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study.
Derlin T; Werner RA; Lafos M; Henkenberens C; von Klot CAJ; Sommerlath Sohns JM; Ross TL; Bengel FM
J Nucl Med; 2020 Nov; 61(11):1602-1606. PubMed ID: 32169910
[TBL] [Abstract][Full Text] [Related]
19. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Rahbar K; Ahmadzadehfar H; Kratochwil C; Haberkorn U; Schäfers M; Essler M; Baum RP; Kulkarni HR; Schmidt M; Drzezga A; Bartenstein P; Pfestroff A; Luster M; Lützen U; Marx M; Prasad V; Brenner W; Heinzel A; Mottaghy FM; Ruf J; Meyer PT; Heuschkel M; Eveslage M; Bögemann M; Fendler WP; Krause BJ
J Nucl Med; 2017 Jan; 58(1):85-90. PubMed ID: 27765862
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Damle NA; Shamim SA; Kumar R; Seth A; Bal C
PLoS One; 2021; 16(5):e0251375. PubMed ID: 33970962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]